Distinguished in Focal Segmental Glomerulosclerosis

Jonathan Barratt

Leicester, ENG, GB 
Distinguished in Focal Segmental Glomerulosclerosis
Leicester, ENG, GB 
OverviewLocationsClinical Research

Overview

Jonathan Barratt practices in Leicester, United Kingdom. Mr. Barratt is rated as a Distinguished expert by MediFind in the treatment of Focal Segmental Glomerulosclerosis. His top areas of expertise are Glomerulonephritis, IgA Nephropathy, Chronic Kidney Disease, Focal Segmental Glomerulosclerosis, and Kidney Transplant.

His clinical research consists of co-authoring 226 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Focal Segmental Glomerulosclerosis.

Gender
Male

Locations

Leicester, ENG, United Kingdom
Other Locations
Southampton, ENG, United Kingdom
Birmingham, ENG, United Kingdom
St Mary's Hospital Foundation Trust
London, ENG, United Kingdom
United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

226 Total Publications

Disease Modification in Immunoglobulin A Nephropathy.
Disease Modification in Immunoglobulin A Nephropathy.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: December 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Barratt's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile